Dager S R, Khan A, Cowley D, Avery D H, Elder J, Roy-Byrne P, Dunner D L
Harborview Medical Center, Seattle, WA 98104.
Psychopharmacol Bull. 1990;26(3):273-8.
Mixed-panic disorder patients (16/60, 27%) randomly assigned to receive blind placebo during a 40-week treatment study were defined as placebo responders based on combined criteria of Hamilton Anxiety Scale score percentage decreases below the median point (-42%), moderate to marked improvement on both clinician and patient Clinical Global Impressions scores, and panic-free at final treatment visit. These criteria applied separately also resulted in a similar clinical grouping and pattern of response. Differential patterns of response between responders and nonresponders occurred across most clinical measures of panic/anxiety. Responders experienced early improvement within the first week of double-blind treatment. This response progressed during treatment and tended to persist during taper and at followup 1 month later. Post-hoc analysis of demographic and clinical features at entrance into the study failed to characterize this stringently defined group of placebo responders.
在一项为期40周的治疗研究中，随机分配接受盲法安慰剂治疗的混合性惊恐障碍患者（16/60，27%），根据汉密尔顿焦虑量表评分下降百分比低于中位数点（-42%）、临床医生和患者临床总体印象评分均有中度至显著改善以及在最后一次治疗访视时无惊恐发作的综合标准，被定义为安慰剂反应者。这些标准单独应用也导致了类似的临床分组和反应模式。在大多数惊恐/焦虑临床指标上，反应者和无反应者之间存在不同的反应模式。反应者在双盲治疗的第一周内就出现了早期改善。这种反应在治疗期间持续进展，并在逐渐减量期间及1个月后的随访中趋于持续。对研究入组时的人口统计学和临床特征进行的事后分析未能对这一严格定义的安慰剂反应者群体进行特征描述。
